Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
SAN DIEGO, March 7, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the following two investor conferences in March:
- 24th Annual Roth Conference in Dana Point on March 14, 2012 at 12:30 p.m. ET/9:30 a.m. PT. Kurt Gustafson , Chief Financial Officer of Halozyme Therapeutics, will provide a corporate overview.
- Barclays Capital 2012 Global Healthcare Conference in Miami on March 14, 2012 at 4:15 p.m. ET/1:15 p.m. PT. Gregory I. Frost , Ph.D., President and Chief Executive Officer of Halozyme Therapeutics, will provide a corporate overview.
(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)
The presentations will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and recordings will be made available for 90 days following the events. To access the live webcasts, please log on to Halozyme's website approximately fifteen minutes prior to the presentations to register and download any necessary audio software.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
aerickson@halozyme.com
SOURCE Halozyme Therapeutics, Inc.
RELATED LINKS
http://www.halozyme.com
More by this Source
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
May 15, 2013, 18:05 ET
Halozyme Reports First Quarter 2013 Financial Results
May 08, 2013, 16:05 ET
Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
May 07, 2013, 16:15 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.